Health expenditure set to reach a fifth of US GDP

17 April 2020
drug_money_big

National Health Expenditure (NHE)  projections in the USA suggest growth in spending could average 5.4% for 2019 to 2028, reaching nearly 20% of gross domestic product (GDP) by the end of the period.

The data, which were recently released by the Centers for Medicare & Medicaid Services (CMS), indicate that spending on drugs at the retail level grew by 3.2% in 2019.

The research shows that Medicare is expected to show the fastest growth in spending of all the major payers, at 7.6%, mainly as a result of high enrollment growth.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical